Gould Robert J 4/A

What Happened

• Robert J. Gould, a director of Fulcrum Therapeutics (FULC), sold 15,000 shares in an open-market transaction on January 2, 2026. The corrected weighted-average price was $10.8726 per share, for aggregate proceeds of approximately $163,089. The shares were sold at prices ranging from $10.60 to $11.33.

Key Details

• Transaction date: 2026-01-02 (reported in this Form 4/A filed 2026-02-04).
• Transaction type/code: Sale (S) — open market.
• Price: Weighted average $10.8726; range $10.60–$11.33 (multiple trades).
• Proceeds: ~$163,089.
• Shares owned after transaction: Not specified in the information provided.
• Footnotes: Sale was effected under a Rule 10b5-1 trading plan adopted August 1, 2025. This is an amended Form 4 correcting the weighted-average price from $11.8726 to $10.8726.
• Timeliness: Original Form 4 was submitted earlier (noted as Jan 6, 2026); this amendment corrects pricing details.

Context

• This was a sale executed under a 10b5-1 plan, which indicates a pre-arranged trading program rather than ad-hoc trading; such sales are often routine and do not necessarily signal a change in the insider’s view of the company. For retail investors, purchases generally carry clearer bullish signals than routine pre-planned sales.